Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?

Skedgel, Chris

Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer? [electronic resource] - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Jan 2016 - 387-394 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1433-7339

10.1007/s00520-015-2805-7 doi


Antineoplastic Combined Chemotherapy Protocols--adverse effects
Breast Neoplasms--drug therapy
Chemotherapy, Adjuvant--adverse effects
Chemotherapy-Induced Febrile Neutropenia--economics
Cost-Benefit Analysis
Cyclophosphamide--administration & dosage
Decision Support Techniques
Docetaxel
Female
Granulocyte Colony-Stimulating Factor--economics
Humans
Middle Aged
Primary Prevention
Quality-Adjusted Life Years
Risk Factors
Taxoids--administration & dosage